Format

Send to

Choose Destination
Pediatr Clin North Am. 2015 Feb;62(1):47-60. doi: 10.1016/j.pcl.2014.09.004.

Biology of childhood acute lymphoblastic leukemia.

Author information

1
Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA. Electronic address: deepa.bhojwani@stjude.org.
2
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA; Department of Pediatrics, University of Tennessee Health Sciences Center, 920 Madison Avenue, Memphis, TN 38163, USA.
3
Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.

Abstract

Giant strides have been made in the management of childhood acute lymphoblastic leukemia (ALL) over previous decades. Extensive collaborative efforts internationally have played a vital role in the remarkable progress made in not only improving therapeutic outcomes but also deciphering the complex biology of childhood ALL. This review summarizes various insights gained from biological studies of childhood ALL, with a focus on recent studies, and also discusses genomic lesions and epigenetic regulatory mechanisms associated with leukemic transformation. The importance of studying the biology of the host so as to understand additional heterogeneity in treatment response and toxicities is highlighted.

KEYWORDS:

Childhood acute lymphoblastic leukemia; Chromosomal alterations; Genomics; Host germline polymorphisms

PMID:
25435111
PMCID:
PMC4250840
DOI:
10.1016/j.pcl.2014.09.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center